Aurora Spine Yönetim

Yönetim kriter kontrolleri 3/4

Aurora Spine CEO'su Trent Northcutt, Feb2012 tarihinde atandı, in görev süresi 13.75 yıldır. in toplam yıllık tazminatı $ 207.63K olup, şirket hissesi ve opsiyonları dahil olmak üzere 65% maaş ve 35% ikramiyelerden oluşmaktadır. şirketin hisselerinin 5.57% ine doğrudan sahiptir ve bu hisseler CA$ 1.17M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 9.1 yıl ve 12.3 yıldır.

Anahtar bilgiler

Trent Northcutt

İcra Kurulu Başkanı

US$207.6k

Toplam tazminat

CEO maaş yüzdesi	64.97%
CEO görev süresi	13.8yrs
CEO sahipliği	5.6%
Yönetim ortalama görev süresi	9.1yrs
Yönetim Kurulu ortalama görev süresi	12.3yrs

Son yönetim güncellemeleri

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Recent updates

Slammed 30% Aurora Spine Corporation (CVE:ASG) Screens Well Here But There Might Be A Catch

Feb 21

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

Oct 19

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Oct 16

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

Aug 14

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Is Aurora Spine (CVE:ASG) A Risky Investment?

May 29

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

Mar 19

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Oct 15

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

May 01

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Dec 22

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aug 23

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

May 04

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Dec 23

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Jun 11

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

Feb 26

Is Aurora Spine (CVE:ASG) A Risky Investment?

Nov 19

CEO Tazminat Analizi

Trent Northcutt'un ücretlendirmesi Aurora Spine'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2025	n/a	n/a	-US$1m
Jun 30 2025	n/a	n/a	-US$1m
Mar 31 2025	n/a	n/a	-US$1m
Dec 31 2024	US$208k	US$135k	-US$1m
Sep 30 2024	n/a	n/a	-US$636k
Jun 30 2024	n/a	n/a	-US$956k
Mar 31 2024	n/a	n/a	-US$1m
Dec 31 2023	US$175k	US$136k	-US$2m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$123k	US$106k	-US$2m
Sep 30 2022	n/a	n/a	-US$2m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	n/a	n/a	-US$2m
Dec 31 2021	US$127k	US$111k	-US$2m
Sep 30 2021	n/a	n/a	-US$1m
Jun 30 2021	n/a	n/a	-US$793k
Mar 31 2021	n/a	n/a	-US$58k
Dec 31 2020	US$143k	US$131k	-US$232k
Sep 30 2020	n/a	n/a	-US$777k
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$143k	US$131k	-US$1m
Sep 30 2019	n/a	n/a	-US$756k
Jun 30 2019	n/a	n/a	-US$199k
Mar 31 2019	n/a	n/a	-US$114k
Dec 31 2018	US$157k	US$125k	-US$68k

Tazminat ve Piyasa: Trent 'ın toplam tazminatı ($USD 207.63K ) Canadian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 160.36K ).

Tazminat ve Kazançlar: Trent şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Trent Northcutt (58 yo)

13.8yrs

Görev süresi

US$207,626

Tazminat

Mr. Trent J. Northcutt is the Chief Executive Officer and President at Aurora Spine Corporation since February 2012. He is a Founder of Aurora Spine Corporation. Mr. Northcutt served as Vice President at S...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Trent Northcutt	Founder	13.8yrs	US$207.63k	5.57% CA$ 1.2m
Chad Clouse	Chief Financial Officer	5.3yrs	US$166.63k	0.0091% CA$ 1.9k
Laszlo Garamszegi	CTO & Founder	12.8yrs	US$151.07k	Veri yok
David Meyer	VP, Chief Legal Officer & Secretary	no data	US$143.07k	Veri yok
Matt Paxton	Executive Vice President of Sales	less than a year	Veri yok	Veri yok
Matthew Goldstone	Chief Commercial Officer	no data	Veri yok	Veri yok

9.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim: ASG 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Trent Northcutt	Founder	12.3yrs	US$207.63k	5.57% CA$ 1.2m
David Rosenkrantz	Independent Chairman	12.3yrs	Veri yok	15.88% CA$ 3.3m
Tracy Graf	Independent Director	12.3yrs	Veri yok	0.65% CA$ 137.0k
Joseph MacLellan	Independent Director	12.3yrs	Veri yok	0.29% CA$ 61.7k
Michael Seid	Independent Director	12.3yrs	Veri yok	0.22% CA$ 46.4k

12.3yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ASG 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 12.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/11/28 20:40
Gün Sonu Hisse Fiyatı	2025/11/26 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Aurora Spine Corporation 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Neal Gilmer	Clarus Securities Inc.

Aurora Spine Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aurora Spine Corporation, Annual General Meeting, Jun 16, 2025

Aurora Spine Corporation Announces the Promotion of Matt Paxton to Executive Vice President of Sales

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

Independent Director recently sold CA$135k worth of stock

Independent Director recently bought CA$105k worth of stock

Recent updates

Third quarter 2025 earnings released: US$0.003 loss per share (vs US$0.001 profit in 3Q 2024)

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Launches New Biologics Portfolio

Aurora Spine Corporation Announces Launch of its DEXA-L™? Anterior Lumbar Interbody Fusion Device

Second quarter 2025 earnings released: US$0.006 loss per share (vs US$0.002 loss in 2Q 2024)

Investors Holding Back On Aurora Spine Corporation (CVE:ASG)

Aurora Spine Corporation Announces Initial Surgeries Using its Aero Lumbar Fusion System

Aurora Spine Corporation Announces the Upcoming Launch of DEXA-L™, A Standalone Anterior Lumbar Interbody Fusion (ALIF) System Built on the Same Award-Winning DEXA Platform

Now 25% overvalued

First quarter 2025 earnings released

Aurora Spine Corporation to Report Q1, 2025 Results on May 22, 2025

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Aurora Spine Corporation to Report Q4, 2024 Results on Apr 28, 2025

Aurora Spine Corporation, Annual General Meeting, Jun 16, 2025

Aurora Spine Corporation Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™? Sacroiliac Joint Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for the Aero™? Facet Fusion System

Aurora Spine Corporation Announces Completion of Enrollment in Groundbreaking REFINE Study

Slammed 30% Aurora Spine Corporation (CVE:ASG) Screens Well Here But There Might Be A Catch

Aurora Spine Corporation Announces the Promotion of Matt Paxton to Executive Vice President of Sales

Third quarter 2024 earnings released

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?